COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • April 2nd, 2024 • Atlantic Coastal Acquisition Corp. II • Biological products, (no disgnostic substances)
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of this 14th day of December, 2019 (the “Effective Date”), by and between AbPro Corporation, a Delaware corporation with its principal place of business at 68 Cummings Park Drive, Woburn, Massachusetts 01801 (“Licensor”), and Abpro Bio International, Inc., a company organized and existing under the laws of the Republic of Korea with its principal place of business at 139, Techno jungang-daero, Yuga-myeon, Dalseong-gun, Daegu, Republic of Korea (“Company”). Licensor and Company are sometimes collectively referred to herein as the “Parties” and each separately as a “Party.”
COLLABORATION AGREEMENTMaterial Transfer Agreement • April 2nd, 2024 • Atlantic Coastal Acquisition Corp. II • Biological products, (no disgnostic substances)
THIS COLLABORATION AGREEMENT (this “Agreement”) is entered into as of this 21st day of September, 2022 (the “Agreement Effective Date”), by and between Abpro Corporation, a Delaware corporation with its principal place of business at 68 Cummings Park Drive, Woburn, Massachusetts 01801 (“Abpro”), and Celltrion, Inc., a company organized and existing under the laws of Korea with its principal place of business at 23, Academy-ro, Yeonsu-gu, Incheon, 22014, the Republic of Korea (“Celltrion”). Abpro and Celltrion are sometimes collectively referred to herein as the “Parties” and each separately as a “Party”.
ContractCollaboration Agreement • April 2nd, 2024 • Atlantic Coastal Acquisition Corp. II • Biological products, (no disgnostic substances) • Hong Kong
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. No./ COLLABORATION AGREEMENT Project: BsAb COLLABORATION AGREEMENT Party A: Abpro Corporation Party B: Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Place of signing: Date of signing: 2019 01 30 Effective Periods:
ContractPublic Health Service • April 2nd, 2024 • Atlantic Coastal Acquisition Corp. II • Biological products, (no disgnostic substances)
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • April 2nd, 2024 • Atlantic Coastal Acquisition Corp. II • Biological products, (no disgnostic substances) • Delaware
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of this 15th day of January, 2020 (the “Effective Date”), by and between AbMed Corporation, a Delaware corporation with its principal place of business at 68 Cummings Park Drive, Woburn, Massachusetts 01801 (“Licensor”), and Abpro Bio International, Inc., a company organized and existing under the laws of the Republic of Korea with its principal place of business at 139, Techno jungang-daero, Yuga-myeon, Dalseong-gun, Daegu, Republic of Korea (“Company”). Licensor and Company are sometimes collectively referred to herein as the “Parties” and each separately as a “Party.”
ABPRO CORPORATIONAtlantic Coastal Acquisition Corp. II • April 2nd, 2024 • Biological products, (no disgnostic substances)
This side letter agreement (this “Letter”) relates to that certain Collaboration and License Agreement, as amended (the “License Agreement”), dated as of August 26, 2016, by and among MedImmune Limited, a company incorporated in England and Wales (“MedImmune”), AbMed Corporation, a Delaware corporation ( “AbMed”), and Abpro Corporation, a Delaware corporation (“Abpro”) (collectively, the “Parties”), and the Stockholders Agreement dated as of August 26, 2016 by and among the Parties (the “Stockholders Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the License Agreement.
LICENSE AGREEMENTLicense Agreement • April 2nd, 2024 • Atlantic Coastal Acquisition Corp. II • Biological products, (no disgnostic substances) • Delaware
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of this 26th day of August, 2016 (the “Effective Date”), by and between MedImmune Limited, a company incorporated in England and Wales (under company number 2451177) whose registered office is Milstein Building, Granta Park, Cambridge, CB21 6GH, UK (“Licensor”), AbMed Corporation a Delaware corporation with its principal place of business at 160 Greentree Drive, Suite 101, Dover, Kent County, Delaware 19904 (“Company”) and, solely with respect to the specified provisions hereof, AbPro Corporation, a Delaware corporation with its principal place of business at 65 Cummings Park Drive, Woburn, Massachusetts 01801 (“AbPro”). Licensor, Company and AbPro are sometimes collectively referred to herein as the “Parties” and each separately as a “Party.”
